Heron Therapeutics (HRTX) Tops Q1 EPS by 3c

Heron Therapeutics (NASDAQ: HRTX) reported Q1 EPS of $0.01, $0.03 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $38.9 million versus the consensus estimate of $34.25 million.

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.

You May Also Be Interested In

• Nscale targets up to $3B in US IPO as soon as September - Bloomberg
• FTC files amicus brief challenging Amgen's Enbrel patent acquisition
• Thunder Mountain Gold closes $5.7M private placement